.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Harvard Business School
Cipla
Novartis
Deloitte
US Department of Justice
Johnson and Johnson
Healthtrust
Queensland Health
Mallinckrodt

Generated: July 25, 2017

DrugPatentWatch Database Preview

EXCEDRIN (MIGRAINE) Drug Profile

« Back to Dashboard

Which patents cover Excedrin (migraine), and what generic Excedrin (migraine) alternatives are available?

Excedrin (migraine) is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There is one patent protecting this drug.

This drug has twelve patent family members in thirteen countries.

The generic ingredient in EXCEDRIN (MIGRAINE) is acetaminophen; aspirin; caffeine. There are sixty-six drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the acetaminophen; aspirin; caffeine profile page.

Summary for Tradename: EXCEDRIN (MIGRAINE)

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Bulk Api Vendors: see list1
Clinical Trials: see list488
Patent Applications: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EXCEDRIN (MIGRAINE) at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons
EXCEDRIN (MIGRAINE)
acetaminophen; aspirin; caffeine
TABLET;ORAL020802-001Jan 14, 1998OTCYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EXCEDRIN (MIGRAINE)

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons
EXCEDRIN (MIGRAINE)
acetaminophen; aspirin; caffeine
TABLET;ORAL020802-001Jan 14, 1998► Subscribe► Subscribe
Glaxosmithkline Cons
EXCEDRIN (MIGRAINE)
acetaminophen; aspirin; caffeine
TABLET;ORAL020802-001Jan 14, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EXCEDRIN (MIGRAINE)

Country Document Number Estimated Expiration
Portugal994714► Subscribe
World Intellectual Property Organization (WIPO)9903475► Subscribe
Taiwan565447► Subscribe
Australia8170598► Subscribe
Germany69814636► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
McKinsey
Julphar
Cipla
US Department of Justice
Citi
Johnson and Johnson
Teva
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot